Canagliflozin
Ki AChE 0.12859 M. It is clinically relevant as patients taking canagliflozin reach a serum drug concentration of 10M, and the brain/serum ratio of canagliflozin is 0.3. Therefore, the amount of canagliflozin penetrating the brain (3 M) is enough to inhibit AChE. Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus.
General
Type : Drug, Multitarget, Sodium-glucose cotransporter 2, Thiophen, Sulfur Compound, Glycoside
Chemical_Nomenclature : (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Canonical SMILES : CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
InChI : InChI=1S\/C24H25FO5S\/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14\/h2-10,19,21-24,26-29H,11-12H2,1H3\/t19-,21-,22+,23-,24+\/m1\/s1
InChIKey : XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
Other name(s) : Invokana || Canagliflozin anhydrous || TA-7284 || JNJ-28431754 || CHEBI:73274 || 6S49DGR869 || DB08907 || SCHEMBL157162 || CHEMBL2048484 || SCHEMBL29499157
MW : 444.5
Formula : C24H25FO5S
CAS_number : 842133-18-0
PubChem : 24812758
UniChem : XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
Target
References (1)
| Title : Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study - Rizvi_2014_CNS.Neurol.Disord.Drug.Targets_13_447 |
| Author(s) : Rizvi SM , Shakil S , Biswas D , Shaikh S , Bagga P , Kamal MA |
| Ref : CNS Neurol Disord Drug Targets , 13 :447 , 2014 |
| Abstract : |
| PubMedSearch : Rizvi_2014_CNS.Neurol.Disord.Drug.Targets_13_447 |
| PubMedID: 24059302 |